Gland Pharma Limited

NSEI:GLAND Stock Report

Market Cap: ₹289.1b

Gland Pharma Valuation

Is GLAND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLAND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLAND (₹1755.05) is trading above our estimate of fair value (₹804.15)

Significantly Below Fair Value: GLAND is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLAND?

Key metric: As GLAND is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GLAND. This is calculated by dividing GLAND's market cap by their current earnings.
What is GLAND's PE Ratio?
PE Ratio41.8x
Earnings₹6.92b
Market Cap₹289.15b

Price to Earnings Ratio vs Peers

How does GLAND's PE Ratio compare to its peers?

The above table shows the PE ratio for GLAND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.8x
506943 J. B. Chemicals & Pharmaceuticals
44.1x19.4%₹269.3b
AJANTPHARM Ajanta Pharma
42.2x16.4%₹369.7b
IPCALAB Ipca Laboratories
61.1x30.0%₹403.7b
EMCURE Emcure Pharmaceuticals
43.8x25.3%₹248.4b
GLAND Gland Pharma
41.8x25.8%₹289.1b

Price-To-Earnings vs Peers: GLAND is good value based on its Price-To-Earnings Ratio (41.8x) compared to the peer average (47.8x).

Price to Earnings Ratio vs Industry

How does GLAND's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$70.43m
524652 Ind-Swift
2xn/aUS$13.12m
No more companies available in this PE range
GLAND 41.8xIndustry Avg. 31.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GLAND is expensive based on its Price-To-Earnings Ratio (41.8x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is GLAND's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLAND PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41.8x
Fair PE Ratio46.7x

Price-To-Earnings vs Fair Ratio: GLAND is good value based on its Price-To-Earnings Ratio (41.8x) compared to the estimated Fair Price-To-Earnings Ratio (46.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLAND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,755.05
₹1,813.25
+3.3%
26.6%₹3,120.00₹1,214.00n/a12
Nov ’25₹1,646.35
₹1,920.25
+16.6%
29.0%₹3,120.00₹1,214.00n/a12
Oct ’25₹1,800.80
₹1,942.75
+7.9%
29.5%₹3,120.00₹1,214.00n/a12
Sep ’25₹1,838.55
₹1,983.58
+7.9%
28.5%₹3,120.00₹1,214.00n/a12
Aug ’25₹2,123.65
₹1,886.58
-11.2%
29.0%₹3,120.00₹1,214.00n/a12
Jul ’25₹1,818.15
₹1,827.33
+0.5%
31.2%₹3,120.00₹873.00n/a12
Jun ’25₹1,840.15
₹1,827.33
-0.7%
31.2%₹3,120.00₹873.00n/a12
May ’25₹1,711.20
₹1,845.25
+7.8%
32.5%₹3,120.00₹873.00n/a12
Apr ’25₹1,813.75
₹1,861.58
+2.6%
30.7%₹3,120.00₹1,130.00n/a12
Mar ’25₹1,787.55
₹1,876.00
+4.9%
29.4%₹3,120.00₹1,130.00n/a13
Feb ’25₹1,983.80
₹1,756.67
-11.4%
31.2%₹3,120.00₹906.00n/a15
Jan ’25₹1,906.55
₹1,669.00
-12.5%
30.3%₹3,120.00₹871.00n/a15
Dec ’24₹1,809.35
₹1,649.00
-8.9%
30.1%₹3,120.00₹871.00n/a15
Nov ’24₹1,533.95
₹1,544.33
+0.7%
34.4%₹3,120.00₹871.00₹1,646.3515
Oct ’24₹1,675.10
₹1,477.67
-11.8%
35.0%₹3,120.00₹871.00₹1,800.8015
Sep ’24₹1,768.10
₹1,477.67
-16.4%
35.0%₹3,120.00₹871.00₹1,838.5515
Aug ’24₹1,303.60
₹1,428.80
+9.6%
38.7%₹3,120.00₹925.00₹2,123.6515
Jul ’24₹1,062.50
₹1,434.80
+35.0%
38.6%₹3,120.00₹925.00₹1,818.1515
Jun ’24₹932.45
₹1,445.44
+55.0%
39.0%₹3,120.00₹925.00₹1,840.1516
May ’24₹1,358.80
₹1,734.67
+27.7%
29.7%₹3,120.00₹1,200.00₹1,711.2015
Apr ’24₹1,268.25
₹1,771.33
+39.7%
28.8%₹3,120.00₹1,200.00₹1,813.7515
Mar ’24₹1,292.75
₹1,990.63
+54.0%
45.0%₹4,930.00₹1,300.00₹1,787.5516
Feb ’24₹1,262.40
₹2,118.88
+67.8%
42.3%₹4,930.00₹1,300.00₹1,983.8017
Jan ’24₹1,576.55
₹2,547.53
+61.6%
27.8%₹4,930.00₹1,660.00₹1,906.5517
Dec ’23₹1,752.95
₹2,538.28
+44.8%
26.9%₹4,930.00₹1,800.00₹1,809.3518
Nov ’23₹1,786.25
₹2,615.78
+46.4%
25.5%₹4,930.00₹1,920.00₹1,533.9518

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Colinz Laboratories

₹138.6m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹55.02

7D

-8.8%

1Y

33.1%